M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection (2017)
Source: Scientific Reports. Unidades: ICB, FMRP
Subjects: IMUNOLOGIA, ALÉRGENOS, INTERLEUCINAS, MACRÓFAGOS, MYCOBACTERIUM TUBERCULOSIS, TUBERCULOSE PULMONAR
ABNT
PIÑEROS, A. R. et al. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Scientific Reports, v. 7, n. 41240, p. 1-12, 2017Tradução . . Disponível em: https://doi.org/10.1038/srep41240. Acesso em: 31 out. 2024.APA
Piñeros, A. R., Campos, L. W., Fonseca, D. M. da, Bertolini, T. B., Gembre, A. F., Prado, R. Q., et al. (2017). M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Scientific Reports, 7( 41240), 1-12. doi:10.1038/srep41240NLM
Piñeros AR, Campos LW, Fonseca DM da, Bertolini TB, Gembre AF, Prado RQ, Alves Filho JCF, Ramos SG, Russo M, Bonato VLD. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection [Internet]. Scientific Reports. 2017 ; 7( 41240): 1-12.[citado 2024 out. 31 ] Available from: https://doi.org/10.1038/srep41240Vancouver
Piñeros AR, Campos LW, Fonseca DM da, Bertolini TB, Gembre AF, Prado RQ, Alves Filho JCF, Ramos SG, Russo M, Bonato VLD. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection [Internet]. Scientific Reports. 2017 ; 7( 41240): 1-12.[citado 2024 out. 31 ] Available from: https://doi.org/10.1038/srep41240